Introduction: The risk of cutaneous malignancies is significantly higher in immunosuppressed patients compared to the general population. These high-risk skin tumors tend to be aggressive, multiplex, rapidly growing lesions. It is common to see local recurrence after surgical excision. Multiplex tumors are difficult to treat, especially in the head/neck region.
Objective: Amongst the standard treatment options, electrochemotherapy can be a suitable option. Our aim was to evaluate the efficacy of electrochemotherapy in immunocompromised patients.
Method: In 9 immunosuppressed patients, 118 (average: 13, n = 5-27) non-melanoma skin tumors were treated with electrochemotherapy with intravenous administration of bleomycin, according to the ESOPE criteria.
Results: The median follow-up was 15 months. 6 months after the treatment, the objective response rate was 96%. We observed complete response in 88%, partial response in 8% and progressive disease in 2% of the treated lesions. In 2%, the response was not evaluable.
Conclusion: In immunocompromised patients, electrochemotherapy is an effective and safe therapeutic option for non-melanoma skin tumors. In order to provide more ideal management for this special sub-group, prevention, multidisciplinary approach and optimized immunosuppressive therapy is essential. Orv Hetil. 2023; 164(37): 1462-1468.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1556/650.2023.32852 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Steroid-refractory immune mediated hepatitis managed with budesonide in patients with metastatic melanoma: proof of concept and literature review.
Oncologist
January 2025
Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, United States.
Immune checkpoint inhibitors (ICIs) have advanced the treatment of metastatic melanoma. However, some patients develop ICI-associated toxicities like hepatitis (ie, immune-mediated hepatitis; IMH). Although these toxicities usually resolve with steroids, steroid-refractory events may occur, which may be a major source of morbidity and mortality without obviously defined treatment algorithms.
View Article and Find Full Text PDFAmid a boom in organ donation, a heightened focus on cancer risk in transplant recipients: Immunosuppression, transmissible infections and tumors, and improved long-term survival among organ recipients are requiring more vigilance for skin cancers and other malignancies.
Cancer Cytopathol
February 2025
Guardians of the Game: UV-Specific Skin Cancer Prevention by Coaches in Outdoor Sports.
Photodermatol Photoimmunol Photomed
January 2025
Center for Preventive Medicine and Digital Health, CPD, Division of Public Health, Social and Preventive Medicine, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany.
Background: Due to the global rise in UV radiation, the prevalence of skin cancer is increasing significantly, with outdoor athletes being identified as a particularly vulnerable population group.
Methods: This nationwide, cross-sectional study was conducted among adult coaches from the 10 largest outdoor sports associations in Germany. Their applied prevention measures and the potential for further improvement in prevention were evaluated by guideline based scores (range [0-100]).
[Role of Community Pharmacies in the Secondary Prevention of Skin Cancer].
Farm Comunitarios
January 2025
Farmacéutica comunitaria en Farmacia Conde Duque en Olivares (Sevilla) España.
Introduction: Skin cancer prevention is a public health priority due to its high incidence and potential to cause significant morbidity and mortality. This study evaluated the effectiveness of an early skin cancer detection program in a community pharmacy, utilizing advanced technologies and interdisciplinary collaboration.
Objectives: 1.
Evaluation of the safety profile of amivantamab based on real-world evidence: a call to vigilance.
Expert Opin Drug Saf
January 2025
Department of Pharmacy, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan, China.
Background: Amivantamab has been approved for EGFR exon 20 insertion-mutated non-small-cell lung cancer. The aim of this study was to perform an in-depth analysis of its safety profile.
Research Design And Methods: Safety reports were collected from the database of the Food and Drug Administration Adverse Event Reporting System from April 2021 to September 2023, and the reporting odds ratio (ROR) method was used to detect potential safety signals.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!